Neoadjuvant Study of Nab-paclitaxel Plus Carboplatin in Breast Cancer
Status:
Unknown status
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
This is a single-center, prospective, single arm phase II study to evaluate the efficacy and
safety of nab-paclitaxel plus carboplatin (with trastuzumab for HER-2 positive patients) as
neoadjuvant therapy in operable locally advanced breast cancer patients. The primary
objective is pCR. The secondary objectives include ORR, 3-yr DFS, OS and safety. The sample
size is 30.